Researchers say this net loss is unlikely to reverse without state and federal policy changes, including PBM reform.
|Articles|November 20, 2006
Anticancer drug treats skin lymphoma
The recently approved Zolinza (vorinostat), the first anticancer drug to be developed by Merck & Co. in 20 years, targets a little-known malignancy that's often mistaken for eczema or psoriasis. Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma, who have progressive, persistent, or recurrent disease on or following two systemic therapies.
Advertisement
Advertisement
Related to this article
At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, discusses his team’s and patients’ experiences in a pharmacist-led antiretroviral initiative.
Zaid Fadul, MD, FS, FAAFP, introduces the Nolla Derm app, what it might mean for pharmacists and their patients, and where AI prescribing is headed in the future.
Among a collection of patients across 15 pharmacies, researchers assessed acceptability and satisfaction with pharmacist-led clinical services.
From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.
Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.
For pharmacies competing with CVS and relying on Caremark to serve patients, the prospect of those businesses operating under separate ownership is significant.
Advertisement
Advertisement